| Year |
Citation |
Score |
| 2024 |
Scalera S, Ricciuti B, Marinelli D, Mazzotta M, Cipriani L, Bon G, Schiavoni G, Terrenato I, Di Federico A, Alessi JV, Fanciulli M, Ciuffreda L, De Nicola F, Goeman F, Caravagna G, ... ... Awad MM, et al. Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38980931 DOI: 10.1158/1078-0432.CCR-24-0626 |
0.39 |
|
| 2024 |
Wang X, Hou K, Ricciuti B, Alessi JV, Li X, Pecci F, Dey R, Luo J, Awad MM, Gusev A, Lin X, Johnson BE, Christiani DC. Additional impact of genetic ancestry over self-reported race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer. Hgg Advances. 100320. PMID 38902927 DOI: 10.1016/j.xhgg.2024.100320 |
0.355 |
|
| 2024 |
Chaunzwa TL, Qian JM, Li Q, Ricciuti B, Nuernberg L, Johnson JW, Weiss J, Zhang Z, MacKay J, Kagiampakis I, Bikiel D, Di Federico A, Alessi JV, Mak RH, Jacob E, ... Awad MM, et al. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy. Jama Oncology. PMID 38780929 DOI: 10.1001/jamaoncol.2024.1120 |
0.374 |
|
| 2024 |
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, et al. Perioperative Nivolumab in Resectable Lung Cancer. The New England Journal of Medicine. 390: 1756-1769. PMID 38749033 DOI: 10.1056/NEJMoa2311926 |
0.372 |
|
| 2024 |
Sholl LM, Awad M, Basu Roy U, Beasley MB, Cartun RW, Hwang DM, Kalemkerian G, Lopez-Rios F, Mino-Kenudson M, Paintal A, Reid K, Ritterhouse L, Souter LA, Swanson PE, Ventura CB, et al. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation. Archives of Pathology & Laboratory Medicine. PMID 38625026 DOI: 10.5858/arpa.2023-0536-CP |
0.396 |
|
| 2024 |
Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, Barrichello A, Vaz VR, Lamberti G, Di Federico A, Gandhi MM, Gazgalis D, Feng WW, Jiang J, Baldacci S, ... ... Awad MM, et al. Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors. Cancer Discovery. PMID 38564707 DOI: 10.1158/2159-8290.CD-23-1217 |
0.339 |
|
| 2024 |
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nature Medicine. PMID 38351187 DOI: 10.1038/s41591-024-02808-y |
0.432 |
|
| 2024 |
Naqash AR, Floudas CS, Aber E, Maoz A, Nassar AH, Adib E, Choucair K, Xiu J, Baca Y, Ricciuti B, Alessi JV, Awad MM, Kim C, Judd J, Raez LE, et al. Influence of Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in -Mutant Non-Small-Cell Lung Cancer. Jco Precision Oncology. 8: e2300371. PMID 38330261 DOI: 10.1200/PO.23.00371 |
0.388 |
|
| 2024 |
Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, Chowdhury A, Li YY, Wang X, Spurr L, Pecci F, Di Federico A, Venkatraman D, Barrichello AP, Gandhi M, ... ... Awad MM, et al. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300580. PMID 38207230 DOI: 10.1200/JCO.23.00580 |
0.461 |
|
| 2023 |
Alessi JV, Price A, Richards AL, Ricciuti B, Wang X, Elkrief A, Pecci F, Di Federico A, Gandhi MM, Lebow ES, Santos PMG, Thor M, Rimner A, Schoenfeld AJ, Chaft JE, ... ... Awad MM, et al. Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. Journal For Immunotherapy of Cancer. 11. PMID 37914383 DOI: 10.1136/jitc-2023-007618 |
0.373 |
|
| 2023 |
Zhu M, Kim J, Deng Q, Ricciuti B, Alessi JV, Eglenen-Polat B, Bender ME, Huang HC, Kowash RR, Cuevas I, Bennett ZT, Gao J, Minna JD, Castrillon DH, Awad MM, et al. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell. PMID 37774698 DOI: 10.1016/j.ccell.2023.09.006 |
0.349 |
|
| 2023 |
Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwana N, Waldron-Lynch M, Davis KL, Giovannini M, ... Awad MM, et al. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review. Clinical Lung Cancer. PMID 37741716 DOI: 10.1016/j.cllc.2023.08.011 |
0.369 |
|
| 2023 |
Elkrief A, Riccuiti B, Alessi JV, Fei T, Kalvin HL, Egger JV, Rizvi H, Thummalapalli R, Lamberti G, Plodkowski A, Hellmann MD, Kris MG, Arcila ME, Baine MK, Rudin CM, ... ... Awad MM, et al. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. The Oncologist. PMID 37589215 DOI: 10.1093/oncolo/oyad197 |
0.484 |
|
| 2023 |
Elkrief A, Alessi JMV, Ricciuti B, Brown S, Rizvi H, Preeshagul IR, Wang X, Pecci F, Di Federico A, Lamberti G, Egger JV, Chaft JE, Rudin CM, Riely GJ, Kris MG, ... ... Awad MM, et al. Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study. Journal For Immunotherapy of Cancer. 11. PMID 37487667 DOI: 10.1136/jitc-2023-006994 |
0.338 |
|
| 2023 |
Alessi JV, Ricciuti B, Wang X, Pecci F, Di Federico A, Lamberti G, Elkrief A, Rodig SJ, Lebow ES, Eicholz JE, Thor M, Rimner A, Schoenfeld AJ, Chaft JE, Johnson BE, ... ... Awad MM, et al. Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC. Nature Communications. 14: 4238. PMID 37454214 DOI: 10.1038/s41467-023-39874-8 |
0.39 |
|
| 2023 |
Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, ... ... Awad MM, et al. Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37432985 DOI: 10.1158/1078-0432.CCR-23-1207 |
0.366 |
|
| 2023 |
Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E, Cheong TC, Leonardi G, Karaca-Atabay E, Campisi M, Poggio T, Menotti M, Ambrogio C, Longo DL, Klaeger S, ... ... Awad MM, et al. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nature Cancer. PMID 37430060 DOI: 10.1038/s43018-023-00591-2 |
0.312 |
|
| 2023 |
Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, Spurr LF, Rizvi H, Luo J, Pecci F, Lamberti G, Recondo G, Venkatraman D, Di Federico A, Gandhi MM, ... ... Awad MM, et al. Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37247843 DOI: 10.1016/j.jtho.2023.05.019 |
0.379 |
|
| 2023 |
Garon EB, Spira AI, Goldberg SB, Chaft JE, Papadimitrakopoulou V, Cascone T, Antonia SJ, Brahmer JR, Camidge DR, Powderly JD, Wozniak AJ, Felip E, Wu S, Ascierto ML, Elgeioushi N, ... Awad MM, et al. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37146752 DOI: 10.1016/j.jtho.2023.04.020 |
0.331 |
|
| 2023 |
Nishino M, Wang X, Ricciuti B, Tseng SC, Park H, Alessi JV, Vaz VR, Hatabu H, Lin X, Christiani DC, Awad MM. Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. European Radiology. PMID 37099174 DOI: 10.1007/s00330-023-09658-1 |
0.38 |
|
| 2023 |
Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, ... ... Awad MM, et al. Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37097610 DOI: 10.1158/1078-0432.CCR-22-3413 |
0.392 |
|
| 2023 |
Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, ... ... Awad MM, et al. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discovery. PMID 37068173 DOI: 10.1158/2159-8290.CD-22-1420 |
0.332 |
|
| 2023 |
Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, ... ... Awad MM, et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics. PMID 37024582 DOI: 10.1038/s41588-023-01355-5 |
0.444 |
|
| 2023 |
Rotow J, Patel JD, Hanley MP, Yu H, Awad M, Goldman JW, Nechushtan H, Scheffler M, Kuo CS, Rajappa S, Harada G, Clifford S, Santucci A, Silva L, Tupper R, et al. Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36996322 DOI: 10.1158/1078-0432.CCR-22-2189 |
0.409 |
|
| 2023 |
Nishino M, Wei Z, Mazzola E, Hino T, Tseng SC, Sanchez ME, Hatabu H, Johnson BE, Awad MM. Tumor Volume Nadir in Patients With -Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib. Jco Precision Oncology. 7: e2200603. PMID 36893377 DOI: 10.1200/PO.22.00603 |
0.418 |
|
| 2023 |
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, et al. Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. Future Oncology (London, England). PMID 36815433 DOI: 10.2217/fon-2023-0007 |
0.364 |
|
| 2023 |
Lamberti G, Aizer A, Ricciuti B, Alessi JV, Pecci F, Tseng SC, Sholl LM, Nishino M, Awad MM. Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With -Mutant Non-Small-Cell Lung Cancer. Jco Precision Oncology. 7: e2200621. PMID 36809054 DOI: 10.1200/PO.22.00621 |
0.351 |
|
| 2023 |
Alessi JV, Elkrief A, Ricciuti B, Wang X, Cortellini A, Vaz VR, Lamberti G, Frias RL, Venkatraman D, Fulgenzi CAM, Pecci F, Recondo G, Di Federico A, Barrichello A, Park H, ... ... Awad MM, et al. Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 36775193 DOI: 10.1016/j.jtho.2023.01.091 |
0.442 |
|
| 2023 |
Ricciuti B, Wang X, Awad MM. Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply. Jama Oncology. PMID 36729462 DOI: 10.1001/jamaoncol.2022.7589 |
0.424 |
|
| 2022 |
Ricciuti B, Awad MM. Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers-The Hunt for Predictive Biomarkers to Optimize Treatment Selection. Jama Oncology. PMID 36520420 DOI: 10.1001/jamaoncol.2022.5801 |
0.33 |
|
| 2022 |
Rakaee M, Adib E, Ricciuti B, Sholl LM, Shi W, Alessi JV, Cortellini A, Fulgenzi CAM, Viola P, Pinato DJ, Hashemi S, Bahce I, Houda I, Ulas EB, Radonic T, ... ... Awad MM, et al. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC. Jama Oncology. PMID 36394839 DOI: 10.1001/jamaoncol.2022.4933 |
0.348 |
|
| 2022 |
Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, Srouji J, Ramesh S, Vyasamneni R, Karki B, Sciuto TE, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. PMID 36027916 DOI: 10.1016/j.ccell.2022.08.003 |
0.311 |
|
| 2022 |
Awad MM, Le Bruchec Y, Lu B, Ye J, Miller JA, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A. Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Frontiers in Oncology. 12: 889996. PMID 35747830 DOI: 10.3389/fonc.2022.889996 |
0.338 |
|
| 2022 |
Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, ... ... Awad MM, et al. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. Jama Oncology. PMID 35708671 DOI: 10.1001/jamaoncol.2022.1981 |
0.466 |
|
| 2022 |
Adib E, Nassar AH, Abou Alaiwi S, Groha S, Akl EW, Sholl LM, Michael KS, Awad MM, Jӓnne PA, Gusev A, Kwiatkowski DJ. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Medicine. 14: 39. PMID 35428358 DOI: 10.1186/s13073-022-01041-x |
0.3 |
|
| 2022 |
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. The New England Journal of Medicine. PMID 35403841 DOI: 10.1056/NEJMoa2202170 |
0.366 |
|
| 2022 |
Cortellini A, Ricciuti B, Vaz VR, Soldato D, Alessi JV, Dall'Olio FG, Banna GL, Muthuramalingam S, Chan S, Majem M, Piedra A, Lamberti G, Andrini E, Addeo A, Friedlaender A, ... ... Awad MM, et al. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. Journal For Immunotherapy of Cancer. 10. PMID 35173031 DOI: 10.1136/jitc-2021-004374 |
0.321 |
|
| 2022 |
Ricciuti B, Son J, Okoro JJ, Mira A, Patrucco E, Eum Y, Wang X, Paranal R, Wang H, Lin M, Haikala HM, Li J, Xu Y, Alessi JV, Chhoeu C, ... ... Awad MM, et al. Comparative analysis and isoform-specific therapeutic vulnerabilities of mutations in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35091439 DOI: 10.1158/1078-0432.CCR-21-2719 |
0.394 |
|
| 2022 |
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, ... ... Awad MM, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. The Lancet. Oncology. PMID 35033226 DOI: 10.1016/S1470-2045(21)00658-6 |
0.384 |
|
| 2021 |
Cheng ML, Milan MSD, Tamen RM, Bertram AA, Michael KS, Ricciuti B, Kehl KL, Awad MM, Sholl LM, Paweletz CP, Jänne PA. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. Jco Precision Oncology. 5: 726-732. PMID 34994618 DOI: 10.1200/PO.21.00029 |
0.341 |
|
| 2021 |
Alessi JV, Ricciuti B, Alden SL, Bertram AA, Lin JJ, Sakhi M, Nishino M, Vaz VR, Lindsay J, Turner MM, Pfaff K, Sharma B, Felt KD, Rodig SJ, Gainor JF, ... Awad MM, et al. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. Journal For Immunotherapy of Cancer. 9. PMID 34824161 DOI: 10.1136/jitc-2021-003536 |
0.429 |
|
| 2021 |
Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, ... ... Awad MM, et al. Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34740862 DOI: 10.1016/j.jtho.2021.10.013 |
0.347 |
|
| 2021 |
Awad MM, Le Bruchec Y, Lu B, Ye J, Miller J, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Frontiers in Oncology. 11: 696512. PMID 34552864 DOI: 10.3389/fonc.2021.696512 |
0.357 |
|
| 2021 |
Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 34487855 DOI: 10.1016/j.annonc.2021.08.2151 |
0.348 |
|
| 2021 |
Ramalingam SS, Thara E, Awad MM, Dowlati A, Haque B, Stinchcombe TE, Dy GK, Spigel DR, Lu S, Iyer Singh N, Tang Y, Teslenko I, Iannotti N. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer. PMID 34478166 DOI: 10.1002/cncr.33885 |
0.458 |
|
| 2021 |
Lee JK, Madison R, Classon A, Gjoerup O, Rosenzweig M, Frampton GM, Alexander BM, Oxnard GR, Venstrom JM, Awad MM, Schrock AB. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. Jco Precision Oncology. 5. PMID 34476332 DOI: 10.1200/PO.21.00122 |
0.41 |
|
| 2021 |
Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, et al. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer (Amsterdam, Netherlands). 160: 78-83. PMID 34461400 DOI: 10.1016/j.lungcan.2021.07.002 |
0.324 |
|
| 2021 |
Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, ... ... Awad MM, et al. Antibiotic-exposed patients with non-small cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 34400292 DOI: 10.1016/j.annonc.2021.08.1744 |
0.365 |
|
| 2021 |
Powell SF, Rodríguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, Rodríguez-Cid J, Kowalski DM, Cheng Y, Kurata T, Awad MM, Lin J, Zhao B, Pietanza MC, Piperdi B, et al. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34265431 DOI: 10.1016/j.jtho.2021.06.020 |
0.351 |
|
| 2021 |
Nishino M, Hong F, Ricciuti B, Hatabu H, Awad MM. Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. Jco Precision Oncology. 5. PMID 34250409 DOI: 10.1200/PO.20.00478 |
0.399 |
|
| 2021 |
Wang X, Ricciuti B, Alessi JV, Nguyen T, Awad MM, Lin X, Johnson BE, Christiani DC. Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. Journal of the National Cancer Institute. PMID 34115098 DOI: 10.1093/jnci/djab116 |
0.349 |
|
| 2021 |
Terraf P, Sholl LM, Davids MS, Awad MM, Garcia EP, MacConaill LE, Dal Cin P, Kim A, Lindeman NI, Stachler M, Hwang DH, Dubuc AM. Twists and Turns from 'Tumor in Tumor' Profiling: Surveillance of CLL leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. Cold Spring Harbor Molecular Case Studies. PMID 34074652 DOI: 10.1101/mcs.a006089 |
0.315 |
|
| 2021 |
Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33845210 DOI: 10.1016/j.jtho.2021.03.024 |
0.367 |
|
| 2021 |
Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). Journal For Immunotherapy of Cancer. 9. PMID 33771889 DOI: 10.1136/jitc-2020-001504 |
0.381 |
|
| 2021 |
Wang X, Ricciuti B, Nguyen T, Li X, Rabin MS, Awad MM, Lin X, Johnson BE, Christiani DC. Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer. Cancer Research. PMID 33653773 DOI: 10.1158/0008-5472.CAN-20-3991 |
0.35 |
|
| 2021 |
Dumbrava EE, Mahipal A, Gao X, Shapiro G, Starr JS, Singh P, Furqan M, Ahrorov A, Hickman D, Gubits A, Attar EC, Awad MM, Das S, Park H. Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies. Journal of Clinical Oncology. 39: TPS3161-TPS3161. DOI: 10.1200/JCO.2021.39.15_SUPPL.TPS3161 |
0.301 |
|
| 2021 |
Alessi JVM, Ricciuti B, Li YY, Gupta H, Lamberti G, Recondo G, Venkatraman D, Nishino M, Cherniack AD, Lindsay J, Sharma B, Pfaff KL, Felt K, Sholl LM, Rodig SJ, ... Awad MM, et al. Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC. Journal of Clinical Oncology. 39: 9119-9119. DOI: 10.1200/JCO.2021.39.15_SUPPL.9119 |
0.352 |
|
| 2021 |
Ricciuti B, Alessi JVM, Li YY, Lawrence MN, Gupta H, Nishino M, Cherniack AD, Sholl LM, Awad MM. DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade. Journal of Clinical Oncology. 39: 9113-9113. DOI: 10.1200/JCO.2021.39.15_SUPPL.9113 |
0.407 |
|
| 2021 |
Arbour KC, Ricciuti B, Rizvi H, Hellmann MD, Yu HA, Ladanyi M, Kris MG, Arcila ME, Rudin CM, Lito P, Awad MM, Riely GJ. Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer. Journal of Clinical Oncology. 39: 9088-9088. DOI: 10.1200/JCO.2021.39.15_SUPPL.9088 |
0.406 |
|
| 2021 |
Ricciuti B, Arbour KC, Alessi JVM, Mahadevan N, Lindsay J, Sinha R, Vokes NI, Recondo G, Lamberti G, Rizvi H, Leonardi GC, Plodkowski AJ, Felt K, Tolstorukov M, Janne PA, ... ... Awad MM, et al. Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer. Journal of Clinical Oncology. 39: 9018-9018. DOI: 10.1200/JCO.2021.39.15_SUPPL.9018 |
0.381 |
|
| 2021 |
Wrangle JM, Awad MM, Badin FB, Rubinstein MP, Bhar P, Garner C, Reddy SK, Soon-Shiong P. Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI). Journal of Clinical Oncology. 39: 2596-2596. DOI: 10.1200/JCO.2021.39.15_SUPPL.2596 |
0.307 |
|
| 2021 |
Ricciuti B, Alessi JV, Alden S, Lamberti G, Vaz V, Barrichello A, Sholl L, Awad M. 312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90% Journal For Immunotherapy of Cancer. 9: A336-A336. DOI: 10.1136/jitc-2021-sitc2021.312 |
0.341 |
|
| 2021 |
Alessi JV, Ricciuti B, Lin-Liu Y, Gupta H, Wang X, Lamberti G, Recondo G, Vaz V, Barrichello A, Nishino M, Cherniack A, Lindsay J, Sharma B, Pfaff K, Felt K, ... ... Awad M, et al. 67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer Journal For Immunotherapy of Cancer. 9: A74-A75. DOI: 10.1136/jitc-2021-sitc2021.067 |
0.402 |
|
| 2021 |
Alden S, Ricciuti B, Spurr L, Gupta H, Lamberti G, Li Y, Sholl L, Cherniack A, Awad M. P33.04 Programmed Death-Ligand 1 (PD-L1) Changes in Non-Small-Cell Lung Cancer (NSCLC): Clinical, Pathologic, and Genomic Correlates Journal of Thoracic Oncology. 16: S406-S407. DOI: 10.1016/J.JTHO.2021.01.673 |
0.374 |
|
| 2021 |
Ricciuti B, Arbour K, Lin J, Vajdi A, Tolstorukov M, Hong L, Zhang J, Vokes N, Li Y, Spurr L, Cherniack A, Recondo G, Lamberti G, Rizvi H, Egger J, ... ... Awad M, et al. P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status Journal of Thoracic Oncology. 16: S341. DOI: 10.1016/J.JTHO.2021.01.532 |
0.355 |
|
| 2021 |
Rotow J, Patel J, Hanley M, Yu H, Goldman J, Nechustan H, Scheffler M, Awad M, Clifford S, Santucci A, Silva L, Tupper R, Oxnard G, Kherani J, Drilon A. FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions Journal of Thoracic Oncology. 16: S230. DOI: 10.1016/J.JTHO.2021.01.150 |
0.422 |
|
| 2020 |
Ricciuti B, Awad MM. What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer? Cancer Journal (Sudbury, Mass.). 26: 485-495. PMID 33298719 DOI: 10.1097/PPO.0000000000000489 |
0.437 |
|
| 2020 |
Nishino M, Hida T, Kravets S, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM. Tumor volume dynamics and tumor growth rate in -rearranged advanced non-small-cell lung cancer treated with crizotinib. European Journal of Radiology Open. 7: 100210. PMID 33102632 DOI: 10.1016/J.Ejro.2019.12.004 |
0.396 |
|
| 2020 |
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 183: 347-362.e24. PMID 33064988 DOI: 10.1016/j.cell.2020.08.053 |
0.366 |
|
| 2020 |
Park H, Hatabu H, Ricciuti B, Aijazi SJ, Awad MM, Nishino M. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. European Journal of Radiology. 132: 109275. PMID 32949913 DOI: 10.1016/J.Ejrad.2020.109275 |
0.428 |
|
| 2020 |
Alessi JV, Ricciuti B, Jiménez-Aguilar E, Hong F, Wei Z, Nishino M, Plodkowski AJ, Sawan P, Luo J, Rizvi H, Carter BW, Heymach JV, Altan M, Hellmann M, Awad M. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status. Journal For Immunotherapy of Cancer. 8. PMID 32753547 DOI: 10.1136/Jitc-2020-001007 |
0.546 |
|
| 2020 |
Baldacci S, Grégoire V, Patrucco E, Chiarle R, Jamme P, Wasielewski E, Descarpentries C, Copin MC, Awad MM, Cortot AB. Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). PMID 32553554 DOI: 10.1016/J.Lungcan.2020.05.008 |
0.567 |
|
| 2020 |
Recondo G, Che J, Jänne PA, Awad MM. Targeting Dysregulation in Cancer. Cancer Discovery. PMID 32532746 DOI: 10.1158/2159-8290.Cd-19-1446 |
0.381 |
|
| 2020 |
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000793. PMID 32468956 DOI: 10.1200/Jco.20.00793 |
0.483 |
|
| 2020 |
Pertejo-Fernandez A, Ricciuti B, Hammond SP, Marty FM, Recondo G, Rangachari D, Costa DB, Awad MM. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer (Amsterdam, Netherlands). PMID 32423643 DOI: 10.1016/J.Lungcan.2020.02.013 |
0.41 |
|
| 2020 |
Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, Lanuti M, D'Ovidio F, Bacchetta M, Sonett JR, Saqi A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. The Lancet. Oncology. PMID 32386568 DOI: 10.1016/S1470-2045(20)30140-6 |
0.532 |
|
| 2020 |
Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32332016 DOI: 10.1158/1078-0432.Ccr-19-3529 |
0.523 |
|
| 2020 |
Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, ... ... Awad MM, et al. Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunology Research. PMID 32321774 DOI: 10.1158/2326-6066.Cir-19-0866 |
0.41 |
|
| 2020 |
Alessi JV, Awad MM. Immunotherapy in lung cancer: effective for patients with poor performance status? The Lancet. Respiratory Medicine. PMID 32199467 DOI: 10.1016/S2213-2600(20)30107-7 |
0.481 |
|
| 2020 |
Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32171752 DOI: 10.1016/J.Annonc.2020.02.017 |
0.478 |
|
| 2020 |
Hellmann MD, Gettinger S, Chow LQM, Gordon M, Awad MM, Cha E, Gong X, Zhou G, Walker C, Leopold L, Heist RS. Phase 1 Study of Epacadostat in Combination With Atezolizumab for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. International Journal of Cancer. PMID 32141617 DOI: 10.1002/Ijc.32951 |
0.434 |
|
| 2020 |
Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, ... ... Awad MM, et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 31: 404-411. PMID 32067682 DOI: 10.1016/J.Annonc.2019.11.015 |
0.505 |
|
| 2020 |
Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, ... ... Awad MM, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034073 DOI: 10.1158/1078-0432.Ccr-19-3608 |
0.379 |
|
| 2020 |
Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, ... ... Awad MM, et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 37: 104-122.e12. PMID 31935369 DOI: 10.1016/J.Ccell.2019.12.006 |
0.442 |
|
| 2020 |
Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nature Medicine. 26: 47-51. PMID 31932802 DOI: 10.1038/S41591-019-0716-8 |
0.509 |
|
| 2020 |
Vora KB, Awad MM. Exclusion rates of patients living with HIV from cancer immunotherapy clinical trials. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E19035 |
0.312 |
|
| 2020 |
Ricciuti B, Arbour KC, Lin JJ, Vokes N, Hoojghan AV, Li YY, Cherniack AD, Recondo G, Lamberti G, Venkatraman D, Rizvi H, Egger JV, Plodkowski AJ, Khosrowjerdi S, Digumarthy SR, ... ... Awad MM, et al. Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15113 |
0.492 |
|
| 2020 |
Alessi JVM, Glass C, Ricciuti B, Spurr LF, Sholl LM, Awad MM. Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38: 9577-9577. DOI: 10.1200/Jco.2020.38.15_Suppl.9577 |
0.471 |
|
| 2020 |
Alessi JVM, Ricciuti B, Aguilar EJ, Hong F, Wei Z, Nishino M, Plodkowski AJ, Sawan P, Luo J, Rizvi H, Carter BW, Heymach J, Altan M, Hellmann MD, Awad MM. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status. Journal of Clinical Oncology. 38: 9568-9568. DOI: 10.1200/Jco.2020.38.15_Suppl.9568 |
0.548 |
|
| 2020 |
Pujol J, Vansteenkiste JF, Paz-Ares LG, Gregorc V, Mazieres J, Awad MM, Janne PA, Chisamore MJ, Hossain A, Chen Y, Beck JT. A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results. Journal of Clinical Oncology. 38: 9562-9562. DOI: 10.1200/Jco.2020.38.15_Suppl.9562 |
0.494 |
|
| 2020 |
Gainor JF, Schneider JG, Gutierrez M, Orcutt JM, Finley GG, Otterson GA, Rybkin II, Reddy PS, Horn L, Brahmer JR, Bastos BR, Awad MM, Hellmann MD, Ramalingam SS, Ready NE, et al. Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2. Journal of Clinical Oncology. 38: 9560-9560. DOI: 10.1200/Jco.2020.38.15_Suppl.9560 |
0.51 |
|
| 2020 |
Luo J, Bandlamudi C, Ricciuti B, Vokes N, Schoenfeld AJ, Egger JV, Sauter JL, Plodkowski AJ, Preeshagul IR, Kris MG, Allen EMV, Taylor BS, Rizvi H, Donoghue M, Awad MM, et al. Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38: 9549-9549. DOI: 10.1200/Jco.2020.38.15_Suppl.9549 |
0.466 |
|
| 2020 |
Awad MM, Lee JK, Madison R, Classon A, Kmak J, Frampton GM, Alexander BM, Venstrom J, Schrock AB. Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms. Journal of Clinical Oncology. 38: 9511-9511. DOI: 10.1200/Jco.2020.38.15_Suppl.9511 |
0.352 |
|
| 2020 |
Camidge DR, Janku F, Martinez-Bueno A, Catenacci DVT, Lee J, Lee S, Dowlati A, Rohrberg KS, Navarro A, Moon YW, Awad MM, Heist RS, Poulsen TT, Yablonovitch A, Fosler L, et al. Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆). Journal of Clinical Oncology. 38: 9510-9510. DOI: 10.1200/Jco.2020.38.15_Suppl.9510 |
0.46 |
|
| 2020 |
Rotow JK, Costa DB, Paweletz CP, Awad MM, Marcoux P, Rangachari D, Barbie DA, Sands J, Cheng ML, Johnson BE, Oxnard GR, Jackman DM, Kwiatkowski DJ, Kehl KL, Izdebski MD, et al. Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38: 9507-9507. DOI: 10.1200/Jco.2020.38.15_Suppl.9507 |
0.471 |
|
| 2020 |
Recondo G, Guo R, Cravero P, Ricciuti B, Falcon C, Vokes N, Kris MG, Leonardi GC, Lamberti G, Nguyen T, Venkatraman D, Sholl LM, Drilon AE, Awad MM. Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38: 9042-9042. DOI: 10.1200/Jco.2020.38.15_Suppl.9042 |
0.466 |
|
| 2020 |
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Czyzewicz G, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gumus M, et al. KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). Journal of Clinical Oncology. 38: 9001-9001. DOI: 10.1200/Jco.2020.38.15_Suppl.9001 |
0.348 |
|
| 2020 |
Ricciuti B, Champagne C, Jones G, Lazarus TS, Adeni AE, Cheng ML, Oxnard GR, Awad MM. Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38: 3518-3518. DOI: 10.1200/Jco.2020.38.15_Suppl.3518 |
0.443 |
|
| 2020 |
Clark J, Ricciuti B, Bolina A, Venkatraman D, Newsom-Davis T, Ottaviani D, Lee K, Awad MM, Pinato DJ. Influence of antibiotic therapy (ATB) on oncological outcomes of metastatic non-small cell lung cancer (mNSCLC) patients treated with chemo-immunotherapy (CIT). Journal of Clinical Oncology. 38: 3080-3080. DOI: 10.1200/Jco.2020.38.15_Suppl.3080 |
0.444 |
|
| 2020 |
Arniella M, Ravi A, Stewart C, Freeman S, Awad M, Forde P, Anagnostou V, Henick B, Riess J, Gibbons D, Pennell N, Velcheti V, Leshchiner I, Kim J, Digumarthy S, et al. Abstract 5902: Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative Cancer Research. 80: 5902-5902. DOI: 10.1158/1538-7445.Am2020-5902 |
0.523 |
|
| 2020 |
Spurr LF, Lamberti G, Li YY, Ricciuti B, Recondo G, Umeton R, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Abstract 5668: Genomic correlates of PD-L1 expression are associated with response to immunotherapy in non-small cell lung cancer Cancer Research. 80: 5668-5668. DOI: 10.1158/1538-7445.Am2020-5668 |
0.448 |
|
| 2020 |
Leonardi GC, Cheong T, Ambrogio C, Chen T, Tai W, Karaca E, Mota I, Libra M, Awad MM, Blasco-Patino R, Chiarle R. Abstract 2400: Strong biological bias for ALK intron 19 breakpoints in NSCLC Cancer Research. 80: 2400-2400. DOI: 10.1158/1538-7445.Am2020-2400 |
0.319 |
|
| 2020 |
Saigi M, Yoshida R, Knelson EH, Mahadevan NR, Vajdi A, Cañadas I, Thai TC, Awad MM, Sánchez-Céspedes M, Barbie DA. Abstract 1012: Determinants of immune evasion in MET driven lung cancer Immunology. 80: 1012-1012. DOI: 10.1158/1538-7445.Am2020-1012 |
0.391 |
|
| 2020 |
Awad M, Spigel D, Garon E, Waqar S, Lisberg A, Moles M, Tepper J, Lamb A, Wanamaker A, Khondker Z, Srouji J, Dong J, Poran A, Balogh K, Bushway M, et al. 364 A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC Journal For Immunotherapy of Cancer. 8: A389-A389. DOI: 10.1136/jitc-2020-sitc2020.0364 |
0.318 |
|
| 2020 |
Ricciuti B, Mahadevan N, Umeton R, Alessi J, Polio A, Vokes N, Leonardi G, Aguilar E, Recondo G, Lamberti G, Lawrence M, Janne P, Allen EV, Sholl L, Awad M. 246 Clinicopathologic and genomic correlates of tumor mutational burden and its impact on PD-(L)1 inhibition efficacy in non-small cell lung cancer according to different PD-L1 expression subgroups Journal For Immunotherapy of Cancer. 8: A266-A267. DOI: 10.1136/jitc-2020-sitc2020.0246 |
0.371 |
|
| 2020 |
Grover S, Ruan A, Srivoleti P, Giobbie-Hurder A, Braschi-Amirfarzan M, Srivastava A, Buchbinder E, Ott P, Hodi FS, Kehl K, Awad M, Rahma O. Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)32037-0 |
0.301 |
|
| 2020 |
Ramalingam S, Thara E, Rao S, Awad M, Dowlati A, Haque B, Veatch A, Stinchcombe T, Dy G, Spigel D, Singh NI, Evilevitch L, Wang Z, Tang Y, Teslenko I, et al. 1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC) Annals of Oncology. 31: S819-S820. DOI: 10.1016/j.annonc.2020.08.1582 |
0.417 |
|
| 2019 |
Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, ... ... Awad MM, et al. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. Jco Precision Oncology. 3. PMID 31832578 DOI: 10.1200/PO.19.00171 |
0.354 |
|
| 2019 |
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, et al. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901674. PMID 31800340 DOI: 10.1200/Jco.19.01674 |
0.346 |
|
| 2019 |
Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RI, Digumarthy S, Liu C, Sauter J, ... ... Awad MM, et al. Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31435660 DOI: 10.1093/Annonc/Mdz288 |
0.486 |
|
| 2019 |
Park H, Sholl LM, Hatabu H, Awad MM, Nishino M. Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology. 190173. PMID 31385753 DOI: 10.1148/Radiol.2019190173 |
0.448 |
|
| 2019 |
Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900189. PMID 31206316 DOI: 10.1200/Jco.19.00189 |
0.502 |
|
| 2019 |
Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer (Amsterdam, Netherlands). 133: 96-102. PMID 31200835 DOI: 10.1016/J.Lungcan.2019.05.011 |
0.532 |
|
| 2019 |
Dagogo-Jack I, Awad MM, Shaw AT. BRAF Mutation Class and Clinical Outcomes-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 3189. PMID 31092613 DOI: 10.1158/1078-0432.Ccr-19-0422 |
0.375 |
|
| 2019 |
Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, ... ... Awad MM, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31086949 DOI: 10.1093/Annonc/Mdz141 |
0.484 |
|
| 2019 |
Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M. Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. Journal of Thoracic Imaging. PMID 30985604 DOI: 10.1097/Rti.0000000000000413 |
0.507 |
|
| 2019 |
Fareed MM, Pike LRG, Bang A, Huynh MA, Taylor A, Spektor A, Awad MM, Ott PA, Krishnan M, Balboni TA, Schoenfeld JD. Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Frontiers in Oncology. 9: 199. PMID 30984622 DOI: 10.3389/fonc.2019.00199 |
0.397 |
|
| 2019 |
Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. Journal For Immunotherapy of Cancer. 7: 87. PMID 30922388 DOI: 10.1186/S40425-019-0572-6 |
0.5 |
|
| 2019 |
Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunology, Immunotherapy : Cii. PMID 30877325 DOI: 10.1007/S00262-019-02321-Z |
0.384 |
|
| 2019 |
Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, Awad MM. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdominal Radiology (New York). PMID 30790009 DOI: 10.1007/S00261-019-01935-2 |
0.497 |
|
| 2019 |
Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801042. PMID 30785829 DOI: 10.1200/Jco.18.01042 |
0.515 |
|
| 2019 |
Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 35: 329. PMID 30753829 DOI: 10.1016/j.ccell.2019.01.011 |
0.413 |
|
| 2019 |
Abu-Sbeih H, Faleck D, Ricciuti B, Mendelsohn R, Naqash AR, Cohen J, Sellers M, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad M, Leonardi G, Johnson D, Pinato D, et al. 775 Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000592636.29532.Cc |
0.31 |
|
| 2019 |
Habib A, Zhang Z, Tanasijevic A, Chen R, Awad MM, Odejide OO, Abel GA. Prevalence of prognostic uncertainty and impact on prognostic discussions in thoracic oncology. Journal of Clinical Oncology. 37: 33-33. DOI: 10.1200/Jco.2019.37.31_Suppl.33 |
0.423 |
|
| 2019 |
Leblebjian H, Duperrault M, Glotzbecker B, Awad MM, Bartel S, McDonnell A, Bunnell CA, Wagner AJ, Hamel LM, Dougherty DW. Outcomes of immunotherapy administration for hospitalized cancer patients. Journal of Clinical Oncology. 37: e18225-e18225. DOI: 10.1200/Jco.2019.37.15_Suppl.E18225 |
0.345 |
|
| 2019 |
Smithy JW, Hwang DH, Li YY, Spurr L, Cherniack AD, Sholl LM, Awad MM. Changes in tumor mutational burden in serially biopsied non-small cell lung cancer. Journal of Clinical Oncology. 37: e14286-e14286. DOI: 10.1200/Jco.2019.37.15_Suppl.E14286 |
0.464 |
|
| 2019 |
Aguilar EJ, Ricciuti B, Gainor JF, Nishino M, Adeni AE, Subegdjo S, Khosrowjerdi S, Peterson R, Digumarthy S, Liu C, Sauter JL, Rizvi H, Arbour KC, Carter BW, Heymach J, ... ... Awad MM, et al. Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%. Journal of Clinical Oncology. 37: 9111-9111. DOI: 10.1200/Jco.2019.37.15_Suppl.9111 |
0.506 |
|
| 2019 |
Brahmer JR, Johnson ML, Dols MC, Viteri Ramirez S, Coves J, Sukari A, Awad MM, Salgia R, Papadimitrakopoulou V, Rajan A, Allred AJ, Wade M, Mason G, Zudaire E, Knoblauch RE, et al. Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies. Journal of Clinical Oncology. 37: 9093-9093. DOI: 10.1200/Jco.2019.37.15_Suppl.9093 |
0.427 |
|
| 2019 |
Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Awad MM. Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer. Journal of Clinical Oncology. 37: 9082-9082. DOI: 10.1200/Jco.2019.37.15_Suppl.9082 |
0.516 |
|
| 2019 |
Ricciuti B, Cheng ML, Recondo G, Nishino M, Umeton R, Sholl LM, Awad MM. DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer. Journal of Clinical Oncology. 37: 9077-9077. DOI: 10.1200/Jco.2019.37.15_Suppl.9077 |
0.411 |
|
| 2019 |
Awad MM, Bruchec YL, Lu B, Miller J, Dumitru CD, Spira AI. Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 37: 9029-9029. DOI: 10.1200/Jco.2019.37.15_Suppl.9029 |
0.478 |
|
| 2019 |
Venkatraman D, Anderson A, Digumarthy S, Lizotte PH, Awad MM. Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM). Journal of Clinical Oncology. 37: 8549-8549. DOI: 10.1200/Jco.2019.37.15_Suppl.8549 |
0.321 |
|
| 2019 |
Skoulidis F, Arbour KC, Hellmann MD, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer J, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, et al. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. Journal of Clinical Oncology. 37: 102-102. DOI: 10.1200/Jco.2019.37.15_Suppl.102 |
0.445 |
|
| 2019 |
Vokes N, Alguilar EJ, Umeton R, Adeni A, Sholl L, Hellmann M, Rizvi H, Awad M, Allen EV. Abstract 2514: Inter-test variability in tumor mutational burden (TMB) quantification and identification of TMB thresholds Cancer Research. 79: 2514-2514. DOI: 10.1158/1538-7445.Am2019-2514 |
0.402 |
|
| 2019 |
Ricciuti B, Cheng M, Recondo G, Umeton R, Nishino M, Sholl L, Awad M. P1.04-04 DNA Damage Response Gene Alterations Are Associated with High Tumor Mutational Burden and Clinical Benefit from PD-1 Axis Inhibition in NSCLC Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.907 |
0.414 |
|
| 2019 |
Skoulidis F, Arbour K, Hellmann M, Patil P, Marmarelis M, Owen D, Awad M, Murray J, Levy B, Hellyer J, Gainor J, Stewart T, Goldberg S, Dimou A, Bestvina C, et al. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.591 |
0.357 |
|
| 2019 |
Recondo G, Bahcall M, Sholl L, Leonardi G, Ricciuti B, Nguyen T, Venkatraman D, Lamberti G, Umeton R, Jänne P, Awad M. MA09.11 Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.573 |
0.485 |
|
| 2019 |
Langer C, Gadgeel S, Borghaei H, Patnaik A, Powell S, Gentzler R, Yang JC, Gubens M, Sequist L, Awad M, Cristescu R, Aurora-Garg D, Albright A, Loboda A, Kobie J, et al. OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.426 |
0.359 |
|
| 2019 |
Ricciuti B, Naqash AR, Henick B, Rangachari D, Naidoo J, Venkatraman D, Lamberti G, Recondo G, Zhang J, Macherla S, Baig S, Walker P, Sehgal K, Umeton R, Sholl L, ... ... Awad M, et al. OA03.07 Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.422 |
0.354 |
|
| 2019 |
Lamberti G, Li Y, Spurr L, Ricciuti B, Recondo G, Umeton R, Sholl L, Cherniak A, Awad M. P2.04-32 Comparison of Clinicopathological and Genomic Characteristics Between NSCLCs with a PD-L1 Tumor Proportion Score of ≥90% vs <1% Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1537 |
0.387 |
|
| 2019 |
Lao-Sirieix S, Heymach J, Forde P, Thomas M, Park K, Besse B, Awad M, Goss G, Rizvi N, Ambrose H, Hanekom W, Fox S, Jewsbury P, Pouliot G, Mortimer P, et al. P2.01-07 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1-Containing Therapy (HUDSON) Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1351 |
0.409 |
|
| 2018 |
Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30224342 DOI: 10.1158/1078-0432.Ccr-18-2062 |
0.413 |
|
| 2018 |
Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin MD, Arbour KC, Plodkowski AJ, Halpenny DF, ... ... Awad MM, et al. PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30165371 DOI: 10.1093/Annonc/Mdy334 |
0.53 |
|
| 2018 |
Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, ... ... Awad MM, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics. PMID 30150660 DOI: 10.1038/S41588-018-0200-2 |
0.37 |
|
| 2018 |
Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, et al. 24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30138764 DOI: 10.1016/J.Jtho.2018.08.004 |
0.4 |
|
| 2018 |
Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, et al. Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30072474 DOI: 10.1158/1078-0432.Ccr-18-0876 |
0.47 |
|
| 2018 |
Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, et al. Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET-Rearranged Lung Cancers. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30017832 DOI: 10.1016/J.Jtho.2018.07.004 |
0.438 |
|
| 2018 |
Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery. PMID 29773717 DOI: 10.1158/2159-8290.Cd-18-0099 |
0.434 |
|
| 2018 |
Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017770305. PMID 29746230 DOI: 10.1200/Jco.2017.77.0305 |
0.478 |
|
| 2018 |
Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. PMID 29731394 DOI: 10.1016/J.Ccell.2018.04.001 |
0.484 |
|
| 2018 |
Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, ... Awad MM, et al. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29631035 DOI: 10.1016/J.Jtho.2018.03.031 |
0.484 |
|
| 2018 |
Abravanel DL, Nishino M, Sholl LM, Ambrogio C, Awad MM. An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29631033 DOI: 10.1016/J.Jtho.2018.03.026 |
0.405 |
|
| 2018 |
Nishino M, Sholl LM, Awad MM, Hatabu H, Armand P, Hodi FS. Sarcoid-like granulomatosis of the lung related to immune-checkpoint inhibitors: Distinct clinical and imaging features of a unique immune-related adverse event. Cancer Immunology Research. PMID 29622582 DOI: 10.1158/2326-6066.Cir-17-0715 |
0.451 |
|
| 2018 |
Hu Y, Ulrich B, Supplee J, Kuang Y, Lizotte PH, Feeney N, Guibert N, Awad MM, Wong KK, Janne PA, Paweletz CP, Oxnard GR. False positive plasma genotyping due to clonal hematopoiesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29567812 DOI: 10.1158/1078-0432.Ccr-18-0143 |
0.351 |
|
| 2018 |
Awad MM, Munteanu M, Zhao Y, Xu L, Samkari A, Paz-Ares LG. ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non–small cell lung cancer (mNSCLC) with high PD-L1 levels. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps9109 |
0.462 |
|
| 2018 |
Johnson ML, Solomon BJ, Awad MM, Cho BC, Gainor JF, Goldberg SB, Keam B, Lee DH, Huang C, Helms H, Barak H, Fasso M, Bleul C, Cha E, Rizvi NA. MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps9105 |
0.484 |
|
| 2018 |
Govindan R, Awad MM, Cleary LD, Moles MA, Gaynor R, Goldstein MJ, Spigel DR. An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps3134 |
0.489 |
|
| 2018 |
Heymach J, Thomas M, Besse B, Forde PM, Awad MM, Goss GD, Park K, Rizvi NA, Lao-Sirieix S, Patel SI, Mortimer PG, Ambrose H, Jewsbury PJ, Sachsenmeier K, Khoja L, et al. An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps3120 |
0.56 |
|
| 2018 |
Awad MM, Bahcall M, Sholl LM, Wilson FH, Paweletz C, Capelletti M, Leonardi GC, Watanabe M, Baba H, Chambers ES, Redig AJ, Nishino M, VanderLaan PA, Costa DB, Imamura Y, et al. Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 9069-9069. DOI: 10.1200/Jco.2018.36.15_Suppl.9069 |
0.512 |
|
| 2018 |
Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Lydon CA, Nguyen T, Iafrate AJ, Lennerz JK, Johnson BE, Shaw AT, Awad MM. BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation. Journal of Clinical Oncology. 36: 9045-9045. DOI: 10.1200/Jco.2018.36.15_Suppl.9045 |
0.469 |
|
| 2018 |
Garon EB, Spira AI, Goldberg SB, Chaft JE, Papadimitrakopoulou V, Antonia SJ, Brahmer JR, Camidge DR, Powderly JD, Wozniak AJ, Felip E, Gao G, Englert JM, Awad MM. Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients. Journal of Clinical Oncology. 36: 9041-9041. DOI: 10.1200/Jco.2018.36.15_Suppl.9041 |
0.356 |
|
| 2018 |
Aguilar EJ, Rizvi H, Kravets S, Lydon CA, Adeni AE, Subegdjo S, Hellmann MD, Awad MM. Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors. Journal of Clinical Oncology. 36: 9037-9037. DOI: 10.1200/Jco.2018.36.15_Suppl.9037 |
0.464 |
|
| 2018 |
Gentzler RD, Langer CJ, Borghaei H, Gadgeel SM, Papadimitrakopoulou V, Patnaik A, Powell SF, Martins RG, Stevenson J, Jalal SI, Panwalkar AW, Yang JC, Gubens MA, Sequist LV, Awad MM, et al. 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. Journal of Clinical Oncology. 36: 9026-9026. DOI: 10.1200/Jco.2018.36.15_Suppl.9026 |
0.362 |
|
| 2018 |
Gainor JF, Rizvi H, Aguilar EJ, Mooradian M, Lydon CA, Anderson D, Tenet M, Sauter JL, Mino-Kenudson M, Shaw AT, Awad MM, Hellmann MD. Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression. Journal of Clinical Oncology. 36: 9011-9011. DOI: 10.1200/Jco.2018.36.15_Suppl.9011 |
0.484 |
|
| 2018 |
Shu CA, Grigg C, Chiuzan C, Garofano RF, Patel V, Hernandez S, Negri T, Sacher AG, Smith-Marrone S, Stoopler M, Gainor JF, Awad MM, D'Ovidio F, Sonett JR, Bacchetta M, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 8532-8532. DOI: 10.1200/Jco.2018.36.15_Suppl.8532 |
0.502 |
|
| 2018 |
Vokes N, Miao D, Margolis C, Liu D, Wankowicz S, Schilling B, Sholl LM, Getz G, Janne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors. Journal of Clinical Oncology. 36: 3036-3036. DOI: 10.1200/Jco.2018.36.15_Suppl.3036 |
0.34 |
|
| 2018 |
Ramalingam SS, Hellmann MD, Awad MM, Borghaei H, Gainor J, Brahmer J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Zerba K, Li X, Geese WJ, Green G, Lestini B, et al. Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568 Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct078 |
0.544 |
|
| 2018 |
Paz-Ares L, Rubin S, Zhao Y, Xu L, Samkari A, Awad M. 195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654) Journal of Thoracic Oncology. 13. DOI: 10.1016/S1556-0864(18)30468-4 |
0.49 |
|
| 2018 |
Hida T, Lydon C, Hatabu H, Johnson B, Awad M, Nishino M. P1.01-35 Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.591 |
0.356 |
|
| 2018 |
Vokes N, Alguilar EJ, Adeni A, Umeton R, Sholl L, Rizvi H, Hellmann M, Awad M, Allen EV. MA19.01 Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.474 |
0.471 |
|
| 2018 |
Mahadevan N, Shivadasani P, Nowak J, Awad M, Sholl L. MA11.10 Identification of Mismatch Repair Deficient Lung Adenocarcinomas Using Targeted Next-Generation Sequencing Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.410 |
0.356 |
|
| 2018 |
Alguilar EJ, Gainor J, Kravets S, Khosrowjerdi S, Lydon C, Adeni A, Subegdjo S, Rizvi H, Hellmann M, Awad M. MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100% Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.343 |
0.411 |
|
| 2018 |
Awad M, Lydon C, Adeni A, Subegdjo S, Jones G, Plagnol V, Beeler J, Oxnard G. P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1709 |
0.336 |
|
| 2018 |
Felip E, Brahmer J, Broderick S, Swanson S, Awad M, Mitsudomi T, Girard N, Kerr K, Spicer J, Cai J, Yang R, Forde P. P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1478 |
0.34 |
|
| 2018 |
Forde P, Heymach J, Thomas M, Park K, Besse B, Awad M, Goss G, Rizvi N, Ambrose H, Jewsbury P, Koetz B, Lao-Sirieix S, Mortimer P, Patel S, Sachsenmeier K, et al. P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON) Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1087 |
0.409 |
|
| 2017 |
Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R. Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget. 8: 92265-92274. PMID 29190913 DOI: 10.18632/Oncotarget.21182 |
0.446 |
|
| 2017 |
Engstrom L, Aranda R, Lee M, Tovar EA, Essenburg C, Madaj ZB, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Banos N, Menéndez C, Hidalgo M, Tassell V, Chao R, ... ... Awad MM, et al. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28765324 DOI: 10.1158/1078-0432.Ccr-17-1192 |
0.427 |
|
| 2017 |
Nishino M, Dahlberg SE, Adeni AE, Lydon C, Hatabu H, Janne PA, Hodi FS, Awad MM. Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28679767 DOI: 10.1158/1078-0432.Ccr-17-1434 |
0.526 |
|
| 2017 |
Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, et al. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28662869 DOI: 10.1016/J.Radonc.2017.06.006 |
0.431 |
|
| 2017 |
Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 28557813 DOI: 10.1097/Cji.0000000000000173 |
0.397 |
|
| 2017 |
Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE, Silkes M, Alam MM, Magee DM, Jones R, Jinushi M, Kulkarni M, Carretero J, Wang X, Warner-Hatten T, Cavanaugh JD, ... ... Awad MM, et al. Interleukin-17A Promotes Lung Tumor Progression Through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28483607 DOI: 10.1016/J.Jtho.2017.04.017 |
0.35 |
|
| 2017 |
Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, et al. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 1403-1410. PMID 28447912 DOI: 10.1200/Jco.2016.70.9352 |
0.477 |
|
| 2017 |
Adeegbe D, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, Castrillon J, Yuan GC, Poudel-Neupane N, Zhang H, ... ... Awad MM, et al. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer. Cancer Discovery. PMID 28408401 DOI: 10.1158/2159-8290.Cd-16-1020 |
0.459 |
|
| 2017 |
Zou T, Awad MM. More valuable than platinum: first-line pembrolizumab in advanced stage non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28327984 DOI: 10.1093/Annonc/Mdx083 |
0.473 |
|
| 2017 |
De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz FA, Bellmunt J, Sonpavde G, Hodi FS, Choueiri TK. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunology Research. PMID 28246107 DOI: 10.1158/2326-6066.Cir-16-0237 |
0.389 |
|
| 2017 |
Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer (Amsterdam, Netherlands). 104: 126-130. PMID 28212994 DOI: 10.1016/J.Lungcan.2016.12.019 |
0.47 |
|
| 2017 |
Forde PM, Chaft JE, Felip E, Broderick S, Girard N, Awad MM, Kerr K, Blackwood-Chirchir A, Yang R, Geese WJ, Brahmer JR. Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC. Journal of Clinical Oncology. 35: TPS8577-TPS8577. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps8577 |
0.441 |
|
| 2017 |
Papadimitrakopoulou V, Gadgeel SM, Borghaei H, Gandhi L, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson J, Jalal SI, Panwalkar AW, Yang JC, Gubens MA, Sequist LV, Awad MM, et al. First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. Journal of Clinical Oncology. 35: 9094-9094. DOI: 10.1200/Jco.2017.35.15_Suppl.9094 |
0.396 |
|
| 2017 |
Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Janne PA, Hodi FS, Awad MM. Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting. Journal of Clinical Oncology. 35: 9087-9087. DOI: 10.1200/Jco.2017.35.15_Suppl.9087 |
0.513 |
|
| 2017 |
Leonardi GC, Gainor JF, Azimi RS, Riess J, Rizvi H, Hellmann MD, Awad MM. Use of PD-1 pathway inhibitors among patients with non-small cell lung cancer (NSCLC) and preexisting autoimmune disorders. Journal of Clinical Oncology. 35: 9081-9081. DOI: 10.1200/Jco.2017.35.15_Suppl.9081 |
0.521 |
|
| 2017 |
Drilon AE, Filleron T, Bergagnini I, Milia J, Hatzoglou V, Velcheti V, Besse B, Mok T, Awad MM, Wolf J, Carbone DP, Camidge DR, Riely GJ, Peled N, Mazieres J, et al. Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers. Journal of Clinical Oncology. 35: 9069-9069. DOI: 10.1200/Jco.2017.35.15_Suppl.9069 |
0.429 |
|
| 2017 |
Skoulidis F, Hellmann MD, Awad MM, Rizvi H, Carter BW, Denning W, Elamin Y, Zhang J, Leonardi GC, Halpenny D, Plodkowski A, Long N, Erasmus JJ, Papadimitrakopoulou V, Wong K, et al. STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma. Journal of Clinical Oncology. 35: 9016-9016. DOI: 10.1200/Jco.2017.35.15_Suppl.9016 |
0.445 |
|
| 2017 |
Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon AE, Noonan S, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda YK, Clark JW, et al. Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 35: 8511-8511. DOI: 10.1200/Jco.2017.35.15_Suppl.8511 |
0.456 |
|
| 2017 |
Adeegbe DO, Liu Y, Lizotte P, Kamihara Y, Awad M, Barbie D, Ritz J, Jones S, Quayle S, Hammerman P, Wong K. Abstract 3682: Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer Cancer Research. 77: 3682-3682. DOI: 10.1158/1538-7445.Am2017-3682 |
0.451 |
|
| 2017 |
Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist L, Awad MM, et al. LBA49Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx440.052 |
0.345 |
|
| 2017 |
Skoulidis F, Hellman M, Awad M, Gainor J, Rizvi H, Carter B, Denning W, Villalobos P, Parra E, Elamin Y, Zhang J, Leonardi G, Halpenny D, Papadimitrakopoulou V, Wistuba I, et al. LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma Annals of Oncology. 28: v467. DOI: 10.1093/Annonc/Mdx380.014 |
0.412 |
|
| 2017 |
Nishino M, Adeni A, Hatabu H, Lydon C, Hida T, Hodi FS, Awad M. P2.07-002 Drug-Related Pneumonitis in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Commercial PD-1 Inhibitors Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.11.061 |
0.529 |
|
| 2017 |
Nishino M, Adeni A, Lydon C, Hatabu H, Jänne P, Hodi FS, Awad M. P1.01-055 Spectrum of Early Progression in Advanced NSCLC Patients Treated with PD-1 Inhibitors: Identifying Markers for Poor Outcome Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.709 |
0.431 |
|
| 2017 |
Skoulidis F, Albacker L, Hellmann M, Awad M, Gainor J, Goldberg M, Schrock A, Gay L, Elvin J, Ross J, Rizvi H, Carter B, Erasmus J, Halpenny D, Plodkowski A, et al. MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC Journal of Thoracic Oncology. 12: S1815. DOI: 10.1016/J.Jtho.2017.09.479 |
0.37 |
|
| 2017 |
Awad M, Bruchec YL, Markelewicz R, Chen P, Fandi A, Spira A. MA 02.03 Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab for Refractory Advanced NSCLC: Results From a Phase 1b Study Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.453 |
0.32 |
|
| 2017 |
Borghaei H, Langer C, Gadgeel S, Papadimitrakopoulou V, Patnaik A, Powell S, Gentzler R, Martins R, Stevenson J, Jalal S, Panwalkar A, Yang JC, Gubens M, Sequist L, Awad M, et al. OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.427 |
0.355 |
|
| 2017 |
Brahmer J, Johnson M, Awad M, Rajan A, Allred A, Knoblauch R, Zudaire E, Lorenzi M, Hassan R. P2.07-058 First-In-Human Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, for Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1314 |
0.456 |
|
| 2017 |
Gautschi O, Milia-Baron J, Filleron T, Wolf J, Carbone D, Owen D, Camidge DR, Narayanan V, Doebele R, Besse B, Remon J, Jänne P, Awad M, Peled N, Byoung C, et al. MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.508 |
0.427 |
|
| 2017 |
Mahadevan N, Adeni A, Hammerman P, Awad M, Gandhi L, Sholl L. MA15.02 Non-Synonymous Mutation Burden in Lung Carcinoma is Associated with Durable Clinical Response to Immune Checkpoint Blockade Journal of Thoracic Oncology. 12: S428-S429. DOI: 10.1016/J.Jtho.2016.11.498 |
0.435 |
|
| 2017 |
Awad M, Mastini C, Patino R, Mologni L, Voena C, Mussolin L, Mach S, Adeni A, Lydon C, Jänne P, Chiarle R. P3.02a-006 Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer: Topic: ALK Biomarkers Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1636 |
0.45 |
|
| 2017 |
Haigentz M, Nemunaitis J, Johnson M, Mohindra N, Eaton K, Patel M, Awad M, Faltaos D, Chen I, Christensen J, Potvin D, Neskorik T, Levisetti M, Garon E. P2.06-008 Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC): Topic: Phase I/II Trials Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1501 |
0.47 |
|
| 2016 |
Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, Hodi FS, Awad MM. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. Journal For Immunotherapy of Cancer. 4: 84. PMID 28018599 DOI: 10.1186/S40425-016-0193-2 |
0.558 |
|
| 2016 |
Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, ... ... Awad MM, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). Jama Oncology. PMID 27892978 DOI: 10.1001/Jamaoncol.2016.3834 |
0.473 |
|
| 2016 |
Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao X, Santos AA, Bittinger MA, Keogh L, Koyama S, Almonte C, English JM, Barlow J, et al. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunology Research. PMID 27856426 DOI: 10.1158/2326-6066.Cir-16-0171 |
0.367 |
|
| 2016 |
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet. Oncology. PMID 27745820 DOI: 10.1016/S1470-2045(16)30498-3 |
0.523 |
|
| 2016 |
Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. Jci Insight. 1: e89014. PMID 27699239 DOI: 10.1172/Jci.Insight.89014 |
0.531 |
|
| 2016 |
Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon C, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR. Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discovery. PMID 27694386 DOI: 10.1158/2159-8290.Cd-16-0686 |
0.479 |
|
| 2016 |
Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, ... ... Awad MM, et al. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. International Journal of Radiation Oncology, Biology, Physics. 96: 406-413. PMID 27598807 DOI: 10.1016/J.Ijrobp.2016.06.006 |
0.447 |
|
| 2016 |
Lizotte PH, Jones RE, Keogh L, Ivanova E, Liu H, Awad MM, Hammerman PS, Gill RR, Richards WG, Barbie DA, Bass AJ, Bueno R, English JM, Bittinger M, Wong KK. Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. Scientific Reports. 6: 31745. PMID 27539742 DOI: 10.1038/Srep31745 |
0.334 |
|
| 2016 |
Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand P, Hodi FS. PD-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27535979 DOI: 10.1158/1078-0432.Ccr-16-1320 |
0.431 |
|
| 2016 |
Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, Hatabu H, Janne PA, Hodi FS, Awad MM. Anti-PD-1 inhibitor-related pneumonitis in non- small cell lung cancer. Cancer Immunology Research. PMID 26865455 DOI: 10.1158/2326-6066.Cir-15-0267 |
0.507 |
|
| 2016 |
Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra Cuentas ER, Wistuba II, Soucheray M, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment. Cancer Research. PMID 26833127 DOI: 10.1158/0008-5472.Can-15-1439 |
0.43 |
|
| 2016 |
Awad MM. Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 879-81. PMID 26786927 DOI: 10.1200/Jco.2015.64.2777 |
0.455 |
|
| 2016 |
Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26729443 DOI: 10.1200/Jco.2015.63.4600 |
0.48 |
|
| 2016 |
de Velasco G, Krajewski KM, Albiges L, Awad MM, Bellmunt J, Hodi FS, Choueiri TK. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunology Research. 4: 12-7. PMID 26589768 DOI: 10.1158/2326-6066.Cir-15-0197 |
0.397 |
|
| 2016 |
Gautschi O, Wolf J, Milia J, Filleron T, Carbone DP, Camidge DR, Shih J, Awad MM, Cabillic F, Peled N, Heuvel MVD, Owen DH, Kris MG, Janne PA, Besse B, et al. Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. Journal of Clinical Oncology. 34: 9014-9014. DOI: 10.1200/Jco.2016.34.15_Suppl.9014 |
0.511 |
|
| 2016 |
Velasco Gd, Je Y, Awad MM, Ott PA, Schutz FAB, Bellmunt J, Sonpavde G, Hodi FS, Choueiri TK. Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients. Journal of Clinical Oncology. 34: 3068-3068. DOI: 10.1200/Jco.2016.34.15_Suppl.3068 |
0.374 |
|
| 2016 |
Nishino M, Ramaiya NH, Awad MM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand P, Hodi FS. PD-1 inhibitor-related pneumonitis in advanced cancer patients. Journal of Clinical Oncology. 34: 3053-3053. DOI: 10.1200/Jco.2016.34.15_Suppl.3053 |
0.409 |
|
| 2016 |
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Awad M, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6 |
0.308 |
|
| 2016 |
Sperduto P, Yang TJ, Beal K, Pan H, Brown P, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle JM, Kirkpatrick J, Mak K, Shih H, ... ... Awad M, et al. BMET-06. IMPROVED SURVIVAL AND PROGNOSTIC ABILITY IN LUNG CANCER PATIENTS WITH BRAIN METASTASES: AN UPDATE OF THE GRADED PROGNOSTIC ASSESSMENT FOR LUNG CANCER USING MOLECULAR MARKERS (LUNG-molGPA) Neuro-Oncology. 18: vi27-vi27. DOI: 10.1093/Neuonc/Now212.106 |
0.463 |
|
| 2016 |
Naghi K, Shamaa S, Atwan N, Awad M. 473P Personalized treatment of advanced non-small cell lung cancer based on excision repair cross-complementation group 1 (ERCC-1) expression Annals of Oncology. 27. DOI: 10.1093/annonc/mdw594.037 |
0.318 |
|
| 2016 |
Langer C, Gaddgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell S, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens MA, Sequist LV, Awad MM, et al. Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw435.45 |
0.352 |
|
| 2016 |
Awad MM, Bittinger MA, Jones RE, Liao X, Kulkarni M, Keogh L, Koyama S, Almonte CG, Santos AA, English JE, Barlow J, Richards WG, Hammerman PS, Rodig SJ, Bueno R, et al. Immune profiling of malignant pleural mesothelioma by flow cytometry identifies distinct T-cell activation and exhaustion phenotypes in PD-L1 positive versus PD-L1 negative tumors Journal of Thoracic Oncology. 11. DOI: 10.1016/J.Jtho.2015.12.029 |
0.355 |
|
| 2015 |
Awad MM, Hammerman PS. Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1993-4. PMID 25918290 DOI: 10.1200/Jco.2015.61.4172 |
0.566 |
|
| 2015 |
Awad MM, Sullivan RJ. Dabrafenib in combination with trametinib for the treatment of metastatic melanoma. Expert Review of Clinical Pharmacology. 8: 25-33. PMID 25473943 DOI: 10.1586/17512433.2015.974556 |
0.388 |
|
| 2015 |
Ivanova E, Jones RE, Awad MM, Bittinger MA, Kulkarni MM, Koyama S, Almonte CG, Santos AA, English JM, Barlow J, Richards WG, Hammerman PS, Rodig SJ, Bueno R, Wong K. Abstract B99: Immune profiling of NSCLC tumors and matching normal lung samples by multicolor flow cytometry Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B99 |
0.444 |
|
| 2014 |
Awad MM, Lax TP, Slawski BR, Shaw AT. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1726-8. PMID 25436807 DOI: 10.1097/Jto.0000000000000350 |
0.47 |
|
| 2014 |
Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, ... ... Awad MM, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (New York, N.Y.). 346: 1480-6. PMID 25394791 DOI: 10.1126/Science.1254721 |
0.445 |
|
| 2014 |
Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clinical Advances in Hematology & Oncology : H&O. 12: 429-39. PMID 25322323 |
0.373 |
|
| 2014 |
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discovery. 4: 662-73. PMID 24675041 DOI: 10.1158/2159-8290.Cd-13-0846 |
0.431 |
|
| 2014 |
Gainor JF, Friboulet L, Katayama R, Awad MM, Lockerman EL, Schultz K, Mahmood S, Nishio M, Yanagitani N, Sequist LV, Mino-Kenudson M, Engelman JA, Shaw AT. Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). Journal of Clinical Oncology. 32: 8031-8031. DOI: 10.1200/Jco.2014.32.15_Suppl.8031 |
0.421 |
|
| 2014 |
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys P, Awad MM, Yanagitani N, Kim S, Pferdekamper A, Li J, Kasibhatla S, Sun F, Sun X, et al. Abstract 957: The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer Cancer Research. 74: 957-957. DOI: 10.1158/1538-7445.Am2014-957 |
0.437 |
|
| 2013 |
Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nature Reviews. Cancer. 13: 772-87. PMID 24132104 DOI: 10.1038/Nrc3612 |
0.341 |
|
| 2013 |
Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4273-81. PMID 23729361 DOI: 10.1158/1078-0432.Ccr-13-0318 |
0.53 |
|
| 2013 |
Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. The New England Journal of Medicine. 368: 2395-401. PMID 23724914 DOI: 10.1056/Nejmoa1215530 |
0.407 |
|
| 2013 |
Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ, Monica V, Yeap BY, Scagliotti GV. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 59-66. PMID 22887466 DOI: 10.1093/Annonc/Mds242 |
0.507 |
|
| 2013 |
Gainor JF, Varghese AM, Ou SI, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, et al. A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 31: 8083-8083. DOI: 10.1200/Jco.2013.31.15_Suppl.8083 |
0.446 |
|
| 2009 |
Khambata-Ford S, Harbison C, Woytowitz D, Awad M, Horak C, Xu LA, Dakhil S, Hermann RC, Lynch TJ, Weber MR. K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8021. PMID 27962801 DOI: 10.1200/Jco.2009.27.15_Suppl.8021 |
0.394 |
|
| 2009 |
Winder T, Zhang W, El-Khoueiry A, Yang D, Pohl A, Lurje G, Rowinsky E, Khambata-Ford S, Langer C, Awad M, Lenz H. Association of a germ-line variant in the K-ras 3' untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4061. PMID 27961592 DOI: 10.1200/Jco.2009.27.15_Suppl.4061 |
0.317 |
|
| 2006 |
Awad MM, Dalal D, Cho E, Amat-Alarcon N, James C, Tichnell C, Tucker A, Russell SD, Bluemke DA, Dietz HC, Calkins H, Judge DP. DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy American Journal of Human Genetics. 79: 136-142. PMID 16773573 DOI: 10.1086/504393 |
0.489 |
|
| 2004 |
Wang Z, Cummins JM, Shen D, Cahill DP, Jallepalli PV, Wang TL, Parsons DW, Traverso G, Awad M, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz SD, Goldberg ML, et al. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Research. 64: 2998-3001. PMID 15126332 DOI: 10.1158/0008-5472.Can-04-0587 |
0.327 |
|
| Show low-probability matches. |